April 18, 2016

Arix Bioscience Has Made $25 Million Commitment to Leading Therapeutics Research Accelerator, BioMotiv

LONDON, APRIL 18, 2016: - Arix Bioscience Limited (Arix Bioscience), formerly Perceptive Bioscience Investments Limited, a global healthcare and life science company supporting medical innovation, announced today it has agreed to provide up to $25 million capital to BioMotiv LLC, a US-based therapeutic accelerator organization providing access to pioneering science in leading universities.

Arix Bioscience sources, finances and develops businesses addressing medical innovation at all stages of development. Arix Bioscience and BioMotiv have formed a strategic investment partnership that will enable wide-ranging support for innovative university-sourced projects and discoveries.

BioMotiv is the for-profit collaborator of The Harrington Project for Discovery & Development, based at University Hospitals in Cleveland, Ohio. The Harrington Project is a $250 million initiative with an aim of identifying, funding, and rapidly advancing the development of medical breakthroughs, primarily in the US.

Arix Bioscience has agreed to provide BioMotiv with capital of $25 million. BioMotiv‘s current portfolio includes seven project companies in development. Two of these project companies, Dual Therapeutics and Orca Pharmaceuticals, have partnership arrangements in place with leading Pharmaceutical companies.

As part of the strategic partnership, Arix Bioscience will have an opportunity to co-invest and spinout project companies from BioMotiv and will nominate a member of its management team to serve as a member of the BioMotiv Advisory Board which oversees the screening and selection of projects.

To date, the Harrington Project has reviewed over 1,500 opportunities from over 110 US and UK institutions and selected more than 50 opportunities for support.

Arix Bioscience was founded by leading figures in the international healthcare and life science sectors; Dr Joe Anderson, Chief Executive Officer (formerly a partner with Abingworth LLP), Jonathan Peacock, Chairman (formerly CFO of Amgen and Novartis Pharma) and Professor Sir Christopher Evans, OBE, Deputy Chairman (one of Europe’s world class entrepreneurs). The company commenced operations with initial funding led by Woodford Investment Management and other institutional investors.

Dr Joe Anderson, Chief Executive Officer of Arix Bioscience, said: “We are delighted to have formed this strategic partnership with BioMotiv and it demonstrates our support for medical innovation at all stages of development. We are pleased to be joining eminent research and investment organizations such as Biogen,Takeda and Charles River Laboratories within BioMotiv. Our corporate strategy is structured in such a way that we are unconstrained by geography or stage of company development. With start up companies, outstanding opportunities are to be found around the world and we are pleased to have already secured relationships with science-based universities in the UK, EU and Australia as well as in the US through BioMotiv and a network of leading academic centres and companies.”

Baiju R. Shah, Chief Executive Officer of BioMotiv, said: “We are very pleased to partner with Arix Bioscience given its renowned leadership team, unique platform, and passion for innovation. Through the partnership, BioMotiv and its companies can leverage Arix’s expertise, networks, and financial support to more rapidly and successfully accelerate breakthrough discoveries into medicines.”

Note to Editors

About Arix Bioscience Limited

Arix Bioscience Limited (formerly Perceptive Bioscience) is a global healthcare and life science company formed by leading figures in the healthcare and life science sectors. Headquartered in London and with an office in New York, Arix Bioscience sources and develops businesses addressing medical innovation at all stages of development and is supported with access to breakthrough academic science. The Company also provides financing as well as operational and strategic direction to businesses to maximize their potential for unmet medical needs of patients. In addition to its commitment to BioMotiv, Arix Bioscience directly supports the development of companies and, with Woodford Investment Management, has committed to provide in aggregate up to £40 million capital to Autolus Limited, a biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies for haematological and solid tumours. Further information: www.arixbioscience.com

About BioMotiv

BioMotiv is the mission-driven research accelerator associated with The Harrington Project for Discovery & Development, a $250 million initiative for advancing medicine. The project is based at the University Hospitals in Cleveland and focuses on the acceleration of breakthrough discoveries nationally in the US from research institutions into therapeutics for patients through an innovative model that efficiently aligns capital and collaborations. BioMotiv leverages an experienced team and advisory board to select, fund, and actively manage and advance a portfolio of programs. Further information: www.biomotiv.com